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Abstract
Research of genetic cardiovascular diseases has lacked of good disease models because
rodents, which are primarily used, differ greatly from humans. The ability to derive human
induced pluripotent stem cells (hiPSCs) from patients carrying inherited cardiac diseases
has revolutionized research in the cardiovascular field. The aim for this chapter is to review
the current hiPSC reprogramming methods and methods for differentiating human
pluripotent stem cells (hPSCs) into cardiomyocytes. The chapter focuses on the published
hiPSC models for hypertrophic cardiomyopathy (HCM) and discusses the challenges
related to modeling this interesting disease using hiPSC technology.
Keywords: cardiac differentiation, cardiomyocyte, disease modeling, human induced
pluripotent stem cell, hypertrophic cardiomyopathy
1. Introduction
The derivation of human embryonic stem cells (hESCs) [1] and, more recently, the invention of
human induced pluripotent stem cells (hiPSCs) [2] have opened new opportunities for research
and cellular therapies in regenerative medicine. These cells, collectively called human pluripo‐
tent stem cells (hPSCs), have the ability to self-renew indefinitely and to differentiate into
derivatives of all three germ layers [1, 2]. Thus, hPSCs provide a potential source of cells for
regenerative medicine applications as well as in vitro modeling of genetic diseases and drug
screening.
Traditionally, hiPSCs have been reprogrammed from skin fibroblasts by virally transferring
four pluripotency factors, specifically octamer-binding transcription factor 3/4 (OCT3/4), sex-
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determining region Y-box 2 (SOX2), Kruppel-like factor 4 (KLF4), and myelocytomatosis viral
oncogene homolog (c-MYC), which integrate into the genome of the target cell [2]. More recent
methods have aimed to produce hiPSCs using non-integrative viral transfection [3], integrative
vectors that can be excised after reprogramming [4], or non-viral delivery methods, such as
the introduction of episomal vectors into target cells using electroporation [5].
hPSCs can be differentiated into cardiomyocytes under laboratory conditions. During the
recent years, the cardiac differentiation methods have developed from embryoid body (EB)
formation [6] and co-culturing hPSCs with mouse endodermal-like cells (END-2) [7] to more
direct differentiation on a monolayer using different growth factors and small molecules [8–
10].
Hypertrophic cardiomyopathy (HCM) is one of the most common genetic cardiac diseases,
with a worldwide prevalence of 1:500. In HCM, the cardiac muscle tissue mainly in the
interventricular septum is thickened. The most severe symptoms of HCM are progressive heart
failure and sudden cardiac death [11]. HCM is caused by more than 1400 mutations, which
reside primarily in genes coding for sarcomeric proteins [12]. The clinical phenotype of the
disease is variable, and most of the patients carrying the mutations live their lives without any
symptoms [11]. Currently, there have been five reports published using HCM patient-specific
hiPSCs for modeling the disease [13–17]. Results from these reports will be reviewed thor‐
oughly in this chapter.
2. Human pluripotent stem cells
hPSCs are defined as undifferentiated cells which have the ability to self-renew indefinitely
and to differentiate into derivatives of all three germ layers: endoderm, mesoderm, and
ectoderm [1, 2]. The first hESC line was derived by Thomson and co-workers in 1998 [1].
Traditionally, hESCs are derived from the inner cell mass (ICM) of the blastocyst but early
blastomeres or morula stage embryos have also been used [18, 19].
For a long time, the scientific community believed that cell differentiation was a one-way route
and that there was no turning back when a cell had passed specific differentiation stages or
reached the fully differentiated state. However, in 2006, Yamanaka and co-workers were able
to reprogram already fully differentiated mouse cells back into the pluripotent stage via
retroviral induction with specific pluripotency factors: Oct3/4, Sox2, Klf4, and c-Myc. These four
transcription factors, so called “Yamanaka factors,” were able to force endogenous pluripo‐
tency genes to be turned on in the transfected cell, changing the cell back to a pluripotent state
[20]. In 2007, the team repeated the reprogramming using human fibroblasts, creating hiPSCs
[2]. Similar to hESCs, hiPSCs also have the ability to self-renew and give rise to all somatic cell
types. Although the discovery of hiPSCs has been a revolutionary invention in the stem cell
field, it would not have been possible without earlier research, including somatic cell nuclear
transfer (SCNT) [21–23], which suggested that the nuclear status of a differentiated cell could
be reverted back to totipotency by factors in the cytoplasm of an oocyte [24].
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Because of their unique properties, hPSCs can be maintained in the laboratory for extended
periods of time in their undifferentiated state and differentiated into various cell types,
including cardiomyocytes [6], retinal pigmented epithelial (RPE) cells [25], neural cells [26],
and hepatocytes [27] (Figure 1). Thus, hPSCs represent a limitless cell source for regenerative
medicine applications as well as for studying developmental processes and genetic diseases.
The groundbreaking discovery of hiPSCs has opened completely new opportunities for disease
modeling and drug screening also in the cardiac field. Conventionally, cardiac diseases have
been modeled using animal models or genetically engineered cell lines. These models often
correlate poorly with the results from human studies. In addition, obtaining cardiac tissue
Figure 1. Human pluripotent stem cells (hPSCs). Human embryonic stem cells (hESCs) are derived from the inner cell
mass (ICM) of a blastocyst. Somatic cells from adult individual are reprogrammed into human induced pluripotent
stem cells (hiPSCs) by transferring exogenous pluripotency factors into the cells. hESCs and hiPSCs, collectively called
hPSCs, have the ability to form all three germ layers. In the laboratory, hPSCs can be cultured for extended periods of
time and differentiated into derivatives of different germ layers, such as hepatocytes, neural cells and cardiomyocytes.
The figure was composed of images from the Servier Medical Art image bank (www.servier.com/Powerpont-image-
bank) and cell pictures from BioMediTech.
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directly from patients for research purposes is difficult, and adult human cardiomyocytes
dedifferentiate rapidly under cell culture conditions and lose their characteristic properties.
With the hiPSC technique, we are able to derive cells directly from a patient and transfer the
same genetic information and mutations into hiPSC-derived cardiomyocytes. Therefore,
hiPSCs have great potential to revolutionize the research of cardiovascular diseases.
2.1. Generation of human induced pluripotent stem cells
In the first conversion of mouse and human fibroblasts into iPSCs, Yamanaka’s group used
the viral transduction of four transcription factors (OCT3/4, SOX2, KLF4, and c-MYC) [2, 20].
This method involved the integration of viral genes into the host cell genome, which involves
a risk of tumorigenicity due to the insertional mutagenesis and uncontrolled gene expression
as well as potential reactivation of the virus [28, 29]. To circumvent these problems, a variety
Figure 2. Reprogramming factors, different delivery methods, and donor cell types used in hiPSC generation. The data
presented in the figure were collected from review articles [28, 30]. MSCs, mesenchymal stem cells; hAFSCs, human
amniotic fluid stem cells.
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of new methods using different non-viral and non-integrative methods have been developed.
Technological options for hiPSC transduction are presented in Figure 2.
Viral transduction can be achieved using either integrating or non-integrating viral vectors. In
2007, two distinct research groups published the first generation of hiPSCs. In the first paper,
the delivery was accomplished using retroviral pMXs vectors [2], while in the second paper,
the transduction was performed using lentiviruses [31]. The proteins, which are needed for
the additional rounds of virus replication and packaging, are deleted from the pMXs vectors.
Retroviral vectors are able to target cells according to their envelope pseudotype and they only
transduce actively dividing cells. Lentiviruses, in contrast, can also transduce non-dividing
cells [28]. Both retro- and lentivirally transferred genes are expected to be silenced during the
reprogramming process through methylation and epigenetic modification [32]. Sometimes,
however, the process is incomplete, which results in partially reprogrammed hiPSC lines [20,
33, 34].
To overcome the problems related to transgene integration into the host genome, excisable
vectors have been engineered based on, for example, Cre-recombinase-mediated excision [4].
In this method, the sequence of the gene to be integrated into the genome is inserted between
two loxP sites in the LTR (long terminal repeat) region of the vector. The integrated transgenes
can be afterwards excised from the genome by transfecting the hiPSCs with Cre-recombinase
[4]. Reprogramming factors in distinct vectors are integrated at independent sites in the
genome, which can lead to genomic instability and genome reorganization when Cre-
recombinase is introduced into the cells. Therefore, polycistronic vectors, which express all
reprogramming factors in one vector separated by 2A sequences, are favored when using this
method [35, 36].
Non-integrative viral methods include the use of Sendai viral and adenoviral vectors. With
these two non-integrative viral methods, the Sendai virus has turned out to be more efficient
for the generation of hiPSCs. Sendai virus vectors replicate their single-stranded RNA in the
cytoplasm without entering the nucleus of the infected cell [3]. In addition, they are able to
infect a wide variety of cell species and tissues by attaching to sialic acid receptors, which are
present on the surface of various cell types [3]. Adenoviral vectors, in contrast, contain DNA,
which is transported to the nucleus of the target cell. However, this adenoviral DNA is not
integrated into the genome, and the expression of the adenoviral genes is thus transient [37, 38].
Non-viral methods are based on delivering genes (DNA), RNA copies of the genes or proteins
to target cells. Different delivery carriers, such as transposons, and methods, including
electroporation and transfection reagents, have been reported. The previously mentioned
polycistronic vectors can also be transferred into target cells without viral delivery through
electroporation [4, 36]. The PiggyBac transposon and transposase system is another integrative
non-viral method used in hiPSC generation [39]. In this method, the transposase enzyme
cleaves the delivered genes from specific cleavage sites in the PiggyBac vector and transfers
them into the target genome. The same enzyme can be used to excise exogenous genes from
the genome after reprogramming [39].
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Methods based on episomal vectors, messenger RNA (mRNA) molecules, or purified protein
have been developed for non-integrative non-viral hiPSC production. Episomal vectors
derived from Epstein–Barr virus (oriP/EBNA1) can be used to introduce reprogramming
factors into cells without a need for viral packaging [5, 40]. The expression of the exogenes is
transient and they disappear from the transfected cells during culture [5]. Lastly, nanoparticles
have been used to improve the efficiency of reprogramming, particularly with mRNA
molecules and proteins [41, 42].
3. Differentiation of human pluripotent stem cells into cardiomyocytes
The heart is the first functional organ that develops during embryogenesis. It develops from
the mesoderm, although signals from adjacent cell populations, especially from the endoderm,
have a significant role in cardiogenesis. The entirety of the development of the human heart
is not yet fully understood; however, many molecular events and factors taking part in the
early stages of cardiomyogenesis have been identified. The three main growth factor families
thought to participate in early mesodermal induction and cardiomyogenesis are the wingless/
INT proteins (WNTs), the fibroblast growth factors (FGFs), and members of transforming
growth factor-beta (TGFβ) superfamily, which include bone morphogenetic protein 4 (BMP4),
Nodal and Activin A [43]. The expression of these factors or their inhibitors in the adjacent
Figure 3. Model of different stages in cardiac differentiation. Transcription factors are presented in cursive and cell sur‐
face markers in normal text. The first precardiac mesoderm cells express the T-box factor Brachyury T and the home‐
domain protein Mixl1 (MIXL1). These cells subsequently activate the mesoderm posterior 1 protein (MESP-1), and the
cardiac mesoderm is formed. NK2 transcription factor-related gene, locus 5 (NKX2.5) and GATA-bonding protein 4
(GATA4) direct the development of embryonic cardiomyocytes. Finally, NKX2.5, together with certain other growth
factors, activates cardiac structural genes, including actin, myosins, and troponins. By activating (green) and inhibiting
(red) signaling pathways, hPSCs can be directed toward cardiac differentiation in vitro [43, 44]. The figure was com‐
posed of images from the Servier Medical Art image bank (www.servier.com/Powerpont-image-bank).
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endoderm occurs at different times, and their combination eventually leads to the induction
of the cardiac mesoderm. After receiving these initial signals, development is directed to more
specific and highly conserved cardiogenesis [43–46].
In vitro differentiation methods mimic the phases of heart development, from the mesoderm
to the cardiac mesoderm, cardiac progenitors, and finally, cardiomyocytes [44]. This process
is regulated by alternating activation and inhibition of the signaling pathways participating
in the cardiomyogenesis (Figure 3). Current cardiac differentiation methods are based on EB
differentiation in suspension, co-culturing the cells with END-2 cells or inducing cardiac
differentiation with different growth factors on a monolayer. The details of the most important
differentiation methods are collected in Table 1.
Platform Basal medium GFs/SMs Description/breakthrough Efficiency Reference
EB-based differentiation methods
Low-
attachment
DMEM + ko-SR – First generation of EBs from
hESCs
– Itskovitz-Eldor et
al. [6]
Low-
attachment
DMEM + FBS – First functional
cardiomyocytes from EBs
30% (cTnI, FC) Kehat et al. [47]
V-96 well RPMI + FBS/
HSA
PVA, BMP4, bFGF,
insulin, AA
Forced aggregation strategy 60–90%
(cTnI, FC)
Burridge et al. [48]
3D microwell DMEM/F-12 +
FBS
– Engineered 3D microwell
coated with Matrigel
18–20%
(beating EBs)
Mohr et al. [49]
Low-
attachment
StemPro34 AA, BMP4, bFGF,
Activin A, VEGF,
DKK1
Serum-free, GF-based EB
method
40–50%
(cTnT, FC)
Yang et al. [50]
Low-
attachment
StemPro34 BMP4, AA, IWR-1,
blebbistatin,
Activin A
Serum-free, GF-based EB
method
90%
(cTnT, FC)
Karakikes et al.
[51]
Methods based on END-2 cells
END-2 DMEM + FBS – First co-culture with END-2
cells
35%
(beating wells)
Mummery et al.
[7]
END-2 DMEM + ko-SR AA Addition of AA and serum-
free medium in END-2 co-
culture
5–20%
(α-actinin,
ICC)
Passier et al. [52]
Low-
attachment
END-2 CM SB203580 Differentiation with
medium conditioned on
END-2
cells
22%
(α-MHC,
cytospin)
Graichen et al. [53]
Low-
attachment
END-2 CM Prostaglandin I2,
AA, SB203580
Differentiation of EBs in
END-2 CM, inhibitory
6–9% Xu et al. [54]
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Platform Basal medium GFs/SMs Description/breakthrough Efficiency Reference
effect of insulin (α-MHC,
cytospin)
Monolayer methods
Matrigel RPMI + B27 Activin A, BMP4 First monolayer
differentiation method
30% (β-MHC,
ICC)
Laflamme et al. [9]
Matrigel RPMI + B27 Activin A, BMP4,
bFGF
Sandwhich method,
Matrigel is applied below
and on top of cells
40–98%
(cTnT, FC)
Zhang et al. [55]
Matrigel RPMI + B27 CHIR99021, IWP2/
IWP4
Protocol exploiting small
molecules modulating Wnt
signaling pathway
80–95%
(cTnT, FC)
Lian et al. [10]
Vitronectin RPMI + albumin AA, CHIR99021,
WNT-C59
Serum- and animal-
component free, defined
differentiation protocol
80–90%
(cTnT, FC)
Burridge et al. [8]
GFs, growth factors; SMs, small molecules; ko-SR, knockout serum replacement; FC, flow cytometry; HSA, human
serum albumin; PVA, polyvinyl alcohol; AA, ascorbic acid; ICC, immunocytochemistry; CM, conditioned medium.
Table 1. Overview of the development of cardiac differentiation methods.
The first hESC-derived cardiomyocytes were isolated from spontaneously formed EBs [6, 47].
EBs are spherical, multicellular, three-dimensional aggregates, which are formed when hPSCs
are detached from the feeder cell layer or the culture matrix and cultured in suspension. In
these EB structures, the hPSCs spontaneously differentiate into all three germ layers. In more
recent versions of EB differentiation protocols, the aim has been to generate more uniformly-
sized EBs, for example, via forced-aggregation using centrifugation [48, 56] or by culturing
hPSCs in microwells coated with Matrigel prior to EB formation [49]. Due to the increased
knowledge of the heart development in recent years, more guided EB differentiation methods
using different growth factors and serum-free basal medium have been developed. Yang and
co-workers were able to generate a population of cardiac progenitor cells by inducing EB
differentiation with Activin A, BMP4, bFGF, vascular endothelial growth factor (VEGF), and
Dickkopf homolog 1 (Dkk-1) [50]. With the protocol of Karakikes et al. [51], almost 100% of
the EBs were beating and 90% of the cells were cTnT positive. In this protocol, the EB formation
is induced by BMP4 and blebbistatin, which inhibits the actin-myosin contraction and suppress
the dissociation-induced apoptosis. After this initial step, the EBs are induced to cardiac
lineages by ascorbic acid, BMP4, Activin A, and finally with IWR-1 [51].
As discussed above, anterior endoderm is located directly posterior to mesoderm in the early
development and the signals from adjacent endoderm initiate the early cardiogenesis. Based
on this fact, Mummery et al. developed a differentiation method in 2003, in which the hPSCs
are plated on top of mitotically inactivated END-2 cells [7, 52]. END-2 cells are derived from
mouse P19 embryonal carcinoma cells, and they provide cell-to-cell contacts and produce
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factors that induce cardiac differentiation. However, medium conditioned on END-2 cells
alone has been used in cardiac differentiation, which suggest that cell-to-cell contacts might
not be needed in the cardiac induction [53, 54]. The exact mechanism how END-2 cells induce
the cardiac differentiation is still unclear. However, a valuable details of cardiac differentiation
has been discovered using these cells. For example, END-2 cells have been shown to remove
insulin from the medium and insulin has been shown to inhibit the differentiation of hPSCs
into cardiac lineages [54, 57]. Although, the efficiency of END-2 co-culture method is quite
low, the method has turned out to be reliable in generating cardiomyocytes from various hPSC
lines.
The increase in understanding the regulatory signaling pathways related to cardiogenesis in
conjunction with advances in hPSC culture methods has enabled the development of more
defined and guided monolayer-based differentiation methods. Monolayer methods begin with
the feeder cell-free culture of hPSCs, in which the feeders are substituted with Matrigel or
Geltrex, or matrix composed of different extracellular matrix (ECM) proteins. The advantage
of monolayer differentiation methods is that the cells are in uniform monolayers and there are
no diffusional barriers, which would prevent the function of growth factors. Thus, differen‐
tiation should be easier to control and reproduce, than in EB or in co-culture methods [44]. In
the first monolayer method published in 2007 by Laflamme and co-workers [9], cells were
directed toward cardiac differentiation by a combination of Activin A and BMP4. One of the
more recent methods, the so-called sandwich method, is based on the combination of ECM
with growth factor signaling [55]. Cells were seeded on Matrigel matrix, and after reaching
90% confluence, Matrigel was added on top of the cells. The sequential application of Activin
A, BMP4, and bFGF on the matrix sandwich resulted in 40–90% pure cardiomyocyte popula‐
tions [55].
As in the case of hPSC culture development, cardiac differentiation is also moving toward
easily scalable, chemically defined, and xeno-free conditions. A group of small molecules has
been identified and applied to replace the recombinant cytokines and unknown factors in the
serum. These molecules either activate or inhibit the WNT and TGFβ-signaling pathways. Two
recent publications are based on the sequential activation and inhibition of the WNT signaling
pathway. At first, the formation of the mesoderm is induced using small molecules, such as
CHIR99021 and BIO for WNT signaling activation [10, 58]. After that, more specific cardiac
differentiation is induced by inhibiting the WNT signaling pathway using small molecules,
such as KY02111 and IWP2 [10, 58].
In 2014, Burridge and co-workers [8] published a chemically defined cardiac differentiation
method. The medium consisted of Roswell Park Memorial Institute (RPMI) basal medium
supplemented with HSA and L-ascorbic acid. Cardiac differentiation was further induced by
the sequential activation and inhibition of WNT signaling by CHIR99021 and WNT-C59,
respectively. They also tested various defined matrices (E-cadherin, vitronectin, vitronectin
peptide, laminin-521, laminin-511, fibronectin, and fibronectin peptide) in combination with
differentiation medium. Laminins were the most promising, but because they are extremely
expensive for large-scale applications, vitronectin was selected for further studies. The final
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protocol resulted in 80–90% pure cardiomyocyte populations for the multiple hPSC lines tested
[8].
Although the differentiation methods for hPSC-derived cardiomyocytes have developed
greatly, the efficiency of differentiation varies to a large degree when using different methods
and cell lines and none of the methods result in a homogenous population of cardiomyocytes
[8, 44, 59]. Homogenous cell populations would be needed, for example, to obtain reliable
results from drug-screening assays [44]. Thus, there is a need for efficient purification methods.
Manual dissection [7] and Percoll gradient separation [60] were the first published methods
for cardiomyocyte purification. However, the yield of pure cardiomyocytes with these
methods was quite low. There are a few cell surfer markers that can be used for fluorescence
activated cell sorting (FACS)-based purification of cardiomyocytes. These markers include
signal regulatory protein α (SIRPA), which is expressed both in cardiac progenitor cells and
in hPSC-derived cardiomyocytes [61], and vascular cell adhesion molecule 1 (VCAM1), which
functions in leukocyte-endothelial cell adhesion but is also expressed in hPSC-derived
cardiomyocytes [62]. One of the most recent method takes advantage of cardiomyocytes’
ability to use lactate as an energy source. When culturing cells in glucose-depleted and lactate-
abundant conditions other cells than cardiomyocytes will not survive [63]. Another interesting
option is the microRNA (miRNA) switch technology, in which the cells are purified based on
their miRNA activity. Heterogenous cell population is transfected with synthetic mRNA,
which comprise cell type specific miRNA target site and fluorescent protein. Cells in which
the target miRNA is absent will translate the fluorescent protein and can be sorted out from
the cardiomyocyte population. Alternatively, miR-Bim-switch can be used, which selectively
induces the apoptosis of cells in which the miRNA is not present [64].
3.1. Characterization of hPSC-derived cardiomyocytes
hPSC-derived cardiomyocytes can be characterized by their structural and biochemical, as well
as by their functional features. The most apparent characteristic of hPSC-derived cardiomyo‐
cytes is their ability to contract spontaneously in culture [7, 47]. The organization of the internal
structures can be studied and analyzed after immunolabeling the sarcomeric proteins [65]. The
ultrastructural features of hPSC-derived cardiomyocytes can be studied in more detail using
electron microscopy (EM). Laurila et al. has recently published a thorough review on different
methods used in functional analysis of hiPSC-derived cardiomyocytes [66]. Shortly, the
electrical properties of hPSC-derived cardiomyocytes can be studied on a cell cluster level
using the microelectrode array (MEA) platform approach [47, 67] or on the single-cell level
using the patch clamp-method [68–70]. Calcium plays a major role in excitation-contraction
coupling process by which an electrical signal is transformed into a mechanical contraction
[71]. The intracellular Ca2+ signaling in hPSC-derived cardiomyocytes on a single-cell level is
studied in vitro using specific fluorescent probes for Ca2+ ions, such as fura-2 [72]. The
mechanical beating behavior of hPSC-derived cardiomyocytes can be analyzed using methods
based on video imaging [73].
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4. Hypertrophic cardiomyopathy
An adult cardiomyocyte is composed of evenly distributed and organized myofibrils, which
are divided into approximately 2.2-μm-long contractile units called sarcomeres. Sarcomeres
are composed of thin actin and thick myosin filaments and Z-discs. The thin filaments are
attached to Z-discs, which separate the sarcomeres from each other. The thin filament is
composed of repeating actin molecules, troponin (Tn) complexes, and α-tropomyosin (TPM1)
molecules. Tn complexes consist of TnT, TnI, and TnC. The Tn complex works together with
TPM1 during cardiac contraction. The thick filament consists of myosin molecules, which are
built upon two units of α- and β-myosin heavy chain (α-MHC, β-MHC) and four myosin light
chain (MLC) molecules. Among the other proteins of the thick filament, myosin-binding
protein C (MYBPC) plays the most important role in the contraction. It contributes to actin-
myosin interactions and cross-bridge formation [74].
When the Ca2+ concentration in the cytosol increases, the Ca2+ binds to TnC leading to a
conformational change in the Tn complex. This leads to TPM1 moving from its inhibitory
position, allowing the head region of the MHC to bind to actin, forming a cross-bridge. Then,
myosin hydrolyzes adenosine triphosphate (ATP), causing the sliding of actin and myosin
filaments and muscle contraction. In addition to the structural proteins mentioned above, the
sarcomere consists of many other important proteins, which together form a stabilized and
organized structure [71].
Cardiomyopathies are diseases that affect the heart muscle and can lead to progressive heart
failure and cardiac death. Cardiomyopathies can either be genetic or acquired, and they can
be divided into groups based on their morphological and functional characteristics. Cardio‐
myopathies include, among others, HCM, dilated cardiomyopathy (DCM), and arrhythmo‐
genic right ventricular cardiomyopathy (ARVC) [75]. HCM is one of the most common genetic
cardiac diseases, with a worldwide prevalence of 1:500, and is the most common cause of
sudden cardiac death among young competing athletes. HCM is inherited in an autosomal
dominant pattern, and the mutations are mainly located in the sarcomeric proteins, which are
responsible for the contraction and relaxation of the cardiomyocyte. The clinical manifestation
of the disease is extremely variable: it has age-related penetrance, and the clinical symptoms
can vary within the same family having the same gene mutation. Together, these facts indicate
that there might be other factors in addition to the actual gene mutation, for example, epige‐
netic and environmental factors, that determine the clinical outcomes of the disease. Although
a large number of mutations have now been identified and related to HCM, the pathophysio‐
logical mechanisms of the disease are still largely unknown [11].
In HCM, the cardiac muscle is thickened (≥15 mm) most commonly in the interventricular
septum separating the right and left ventricles. This thickening, i.e., hypertrophy, can lead to
outflow tract obstruction, which indicates that the passage to the aorta from the left ventricle
becomes narrow and obstructive, disturbing the blood flow. This narrowed outflow induces
a massive overload to the heart and can lead to progressive heart failure. Other severe
complications related to HCM include arrhythmias and sudden cardiac death. However, most
individuals remain asymptomatic for their whole lives, and it has been estimated that the
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actual prevalence of the disease might even be 1:200 in the general population [11]. Penetrance
indicates the percentage of mutation carriers who experience the phenotype of the disease. In
HCM, the penetrance is highly variable: it can be age-related or even incomplete and related
to gender [76].
There is no specific cure for this disease and all the complications related to HCM should be
treated individually. Patients are typically asymptomatic for a long time. Often, the first sign
is diastolic heart failure, while systolic heart failure can develop later. Treatments include beta-
blockers or Ca2+-channel blockers for relieving symptoms such as chest pain and shortness of
breath and implantable cardioverter defibrillators (ICDs) for those patients who have survived
cardiac arrest. The actual hypertrophy can be treated by surgical myectomy, which indicates
removing a small portion of the thickened cardiac tissue; via ethanol ablation, in which a
myocardial infarction is induced in the septal area; or at the end-stage via heart transplantation
[11]. Histologically, HCM is characterized by myocyte hypertrophy (diameter >40 μm);
disorganization of myocyte bundles, individual myocytes, and sarcomeres; and fibrosis of
heart tissue. Nuclei are hyperchromatic (contain an abundance of chromatin), pleomorphic
(vary in size and shape), and often enlarged [77].
HCM is inherited in an autosomal dominant pattern and is caused by over 1400 mutations
found in eleven or more genes coding primarily for sarcomeric proteins. Approximately 70%
of patients have a gene mutation either in the MYH7 or MYBPC3 genes while mutations in
other genes are far less common [11, 12]. Rarer mutations are located in Z-disc genes or calcium
handling and regulation genes. One interesting feature of HCM mutations is that they are
almost all identified only in one or a few families [76]. Typically, patients carry only one
heterozygous mutation in a single allele. However, lately, double or even greater numbers of
mutations have been reported to be found in one patient, which might affect the clinical
variance related to the disease [76, 78]. Most pathogenic mutations are missense mutations in
which a single nucleotide is changed, resulting in an amino acid substitution. Missense
mutations are thought to act in a dominant negative manner. Thus, the mutated protein is
produced and interferes with the normal function of the sarcomere. Nonsense mutations, in
contrast, lead to a premature stop codon and truncated proteins. These mutations are thought
to result in haploinsufficiency, in which the mutated protein is either degraded or not produced
at all. The majority of the gene mutations in MYBPC3 are thought to act through this mecha‐
nism [74, 76].
In Finland, two founder mutations in genes coding for MYBPC and TPM1 proteins account
for approximately 18% of Finnish HCM cases, and these MYBPC3-Gln1061X and TPM1-
Asp175Asn mutations are relatively uncommon in other countries besides Finland [79].
MYBPC3-Gln1061X is a nonsense mutation leading to a premature stop-codon and a truncated
MYBPC protein lacking the binding sites for both myosin and titin [80]. This mutation, similar
to other mutations in MYBPC3, is characterized by age-related penetrance and late onset of
the disease [80–82]. TPM1-Asp175Asn is a missense mutation that leads to the substitution of
aspartic acid with asparagine in codon 175 [83]. Originally, MYBPC3-Gln1061X was associated
with a clinically mild phenotype, and TPM1-Asp175Asn was associated with a clinically
intermediate phenotype with a substantial risk for sudden cardiac death. Additionally,
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patients with MYBPC3-Gln1061X were suggested to be more prone to cardiac dilation and
heart failure [84]. However, in the most recent studies, both mutations were associated with
variable left ventricular hypertrophy, and no clear genotype-phenotype correlations could be
verified in clinical studies [79, 85].
Different animal models have been used to study HCM in vitro. These animals include cats,
which have certain naturally occurring HCM mutations, and genetically engineered mice, rats,
rabbits, and Drosophila [86]. Additionally, HCM patient tissues obtained from myectomy
samples have been studied [87]. One of the major difficulties in studying the pathophysiolog‐
ical mechanisms of HCM has been the lack of tissue samples at early stages of disease devel‐
opment. While animal models have provided valuable insight into disease mechanisms, they
contain only the mutated gene and not the rest of the genome, which might have effects on
disease phenotype and progression. Thus, given that they contain the whole genomes of HCM
patients, in addition to the fact that they are cell of human origin, hiPSC-derived cardiomyo‐
cytes represent a valuable new tool for modeling HCM in vitro.
4.1. Human induced pluripotent stem cell models for studying hypertrophic
cardiomyopathy
To date, morphological and functional characteristics of cardiomyocytes, derived from HCM
patient-specific hiPSCs, have been studied in five different reports [13–17]. The results
presented in these publications are collected in Table 2. Cardiomyocytes have been obtained
with different cardiac differentiation methods in each publication. In our report, we have
differentiated hiPSCs into cardiomyocytes using END-2 co-culture method [15]. In addition,
HCM hiPSC-derived cardiomyocytes carrying MYBPC3-c.2373dupG mutation were used in
one report, in which the effects of serum on hypertrophic phenotypes were studied [88]. In
this particular study, serum was found to mask the hypertrophic phenotype of hiPSC-derived
cardiomyocytes with the MYBPC3-c.2373dupG mutation [88]. Serum increased the cell size of
neonatal rat cardiomyocytes as well as cardiomyocytes derived from hESCs and control
hiPSCs. However, the size of the hiPSC-derived cardiomyocytes with the MYBPC3-c.
2373dupG mutation was smaller than that of hiPSC-derived control cardiomyocytes in the
presence of serum. Under serum-free conditions, hiPSC-derived cardiomyocytes with the
MYBPC3-c.2373dupG mutation were significantly larger than hiPSC-derived control cardio‐
myocytes [88]. Conversely, in our study, cardiomyocytes carrying the MYBPC3-Gln1061X
mutation were enlarged, despite the 20% FBS used in the culture medium, challenging the role
of serum in masking the hypertrophic phenotype of hiPSC-derived cardiomyocytes [15].
Patients, mutations and
hiPSCs
HCM phenotype in hiPSC-CMs Drug treatments/other findings
Lan et al. [16]
Family with HCM
–5 pers. with MYH7-
Arg663His
–5 pers. without mutation
Morphological properties
Cellular enlargement, multinucleation,
increased myofibril content, disorganized
sarcomeres
Biochemical properties
Calcineurin-NFAT signaling
Blockade by cyclosporin A and FK506
reduced hypertrophy
β-adrenergic stimulation
Isoproterenol increased cell size and
Modeling Hypertrophic Cardiomyopathy with Human Induced Pluripotent Stem Cells
http://dx.doi.org/10.5772/62649
239
Patients, mutations and
hiPSCs
HCM phenotype in hiPSC-CMs Drug treatments/other findings
(used as control)
Timepoints:
20, 30, 40 days
Upregulation of ANF, TNNT2, MYL2, MYH7,
GATA4 and MEF2c
Elevation of MYH7/MYH6 ratio
Nuclear translocation of NFAT
Ca2+ handling properties
Ca2+ transient irregularities
Elevation of intracellular [Ca2+]
Smaller SR Ca2+ release
Electrophysiological and mechanical
properties
Arrhythmic waveforms including frequent
DADs
Irregular beating observed in video
recordings
Amount of irregular Ca2+ transients and
arrhythmia
Isoproterenol together with propanolol
abolished Ca2+ abnormalities, arrhytmia and
hypertrophy
Blockade of L-type Ca2+ channel
Treatment with verapamil for 5 days
ameliorated HCM phenotype
Diltiazem abolished Ca2+ abnormalities and
arrhythmia
Han et al. [14]
One patient:
- MYH7-Arg442Gly
Two control hiPSC lines
from unrelated donors
Morphological changes
Cellular enlargement,
disorganized sarcomeres
Disorganized Z lines in TEM
Biochemical changes
Changes in (whole
transcriptome sequencing):
 wnt/β-catenin pathway
 Notch signaling pathway
 FGF pathway
Nuclear translocation of NFAT
Decreased level of RYR2, SERCA2
Ca2+ handling properties
Ca2+ transient irregularities
elevation of intracellular [Ca2+]
Smaller SR Ca2+ release
Delayed Ca2+ transient decay time
Electrophysiological properties
Prolonged and dispersed
interspike intervals and increase
of arrhythmogenic events in MEA
Irregular contractility in real-
time cell analyzer APD prolongation
Changes in the shape of AP
Increased Ca2+, Na+ and outward K+ currents
β-adrenergic stimulation
Isoproterenol elevated premature beats and
irregular beating rates
Isopoterenol together with metoprolol
decreased beating irregularity and
arrhythmia
Blockade of L-type Ca2+channel
Treatment with verapamil for 4 days
reduced arrhythmia and Ca2+ handling
abnormalities
KATP channel opener
Antihypertensive drug pinacidil induced
irregular interspike intervals
Inhibition of histone deacetylase activity
Treatment with trichostatin A for 3 days
decreased cell size, nuclear translocation of
NFAT, suppressed Ca2+ abnormalities and
decreased resting [Ca2+]
Tanaka et al. [17]
Three patients:
Morphology without stimulation
Mildly but significantly larger cell size
Stimulation with hypertrophic factors
Angiotensin II, IGF-1, phenylephrine
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Patients, mutations and
hiPSCs
HCM phenotype in hiPSC-CMs Drug treatments/other findings
–MYBPC3-GLY999-
Gln1004del
–TMP1-Arg91Cys
(identified later)
–Mutation unknown
Two control hiPSC lines
from
Unrelated donors
Timepoints:
30, 60, 90 days culture as
EBs
No time-dependent changes in cell size
Myofibrillar disarray in EM and cTnT staining
(>60d, >90d)
cTnT and ANP protein levels higher
MYBPC level lower in hiPSC-CMs with
MYBPC3 mutation
Mildly disorganized contractile form in video
analysis
No difference to non-stimulated cells
Endothelin 1 (ET-1)
 Increased cell size and disarray
 Nuclear translocation of NFAT
 Disorganized contraction
 Similar response in mouse MYBPC+/-
Blocking of ET-1 signaling
ETA-b was able to block ET-1 induced
hypertrophic phenotype
ETB-b had no effect
Birket et al. [13]
(hiPSC lines published in
Dambrot et al. [88]
Three patients:
–MYBPC3-c.2373.dupG
–One hiPSC line from
each
One control hiPSC line
from unrelated donor
Biochemical properties
Decreased level of MYBPC relative to
α-actinin
Stimulation with (T3, IGF-1, Dex) TID
Decreased traction stress
Decreased traction force
No difference in the cell size or contraction
frequencies when compared to controls
Similar findings in MYBPC knockdown
hESC-derived cardiomyocytes
Ojala et al. [15]
Four patients:
–2 pers. with MYBPC3-
Gln1061X
–2 pers. with TPM1-
Asp175Asn
Two control hiPSC lines
from unrelated donors
Timepoints: 1w, 3w, 6w
(as single cells)
Morphological properties
Cellular enlargement, multinucleation
Biochemical properties
Upregulation of MYBPC3, TNNT2, ACTN2,
TTN
MYL7 and MYL9
MYBPC level slightly reduced in MYBPC3-
Gln1061X cells
Ca2+ handling properties
Ca2+ transient irregularities
Electrophysiological and mechanical
properties
Arrhythmic waveforms including frequent
EADs and DADs
Differences between mutations
MYBPC3-Gln1061X cells significantly larger
Differences in expressions of various cardiac
genes
More abnormal Ca2+ signals in TPM1-
Asp175Asn mutation
More prolonged APD in TPM1-Asp175Asn
mutation
MYBPC3-Gln1061X mutation was not
detected in mRNA or protein level
hiPSC-CM, human induced pluripotent stem cell-derived cardiomyocyte; SR, sarcomeric reticulum; DAD, delayed
after depolarization; EM, electron microscopy; MEA, microelectrode array; APD, action potential duration; AP, action
potential; T3 triiodothyronine hormone; IGF, insulin-like growth factor 1; Dex, dexamethasone; EAD, early after
depolarization.
Table 2. Summary of results from published reports using HCM patient-specific hiPSCs.
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Lan et al. published the first report of HCM hiPSC-derived cardiomyocytes in 2013. In their
publication, hiPSCs were established via the lentiviral infection of fibroblasts derived from
five patients carrying the MYH7-Arg663His mutation and from five related healthy individu‐
als. Although the two youngest patients had not developed the clinical phenotype of HCM,
the hiPSC-derived cardiomyocytes from all patients were significantly larger than the control
cardiomyocytes [16]. In 2014, Han et al. published a report in which hiPSCs were derived from
a single patient carrying a MYH7-Arg442Gly mutation. Control hiPSCs were derived from two
unrelated healthy individuals. Fibroblasts were used as a cell source for all established hiPSC
lines, and the infection was performed using retroviruses [14]. Tanaka et al. [17] derived hiPSCs
from three unrelated HCM patients and three healthy volunteers in 2014. One of the HCM
patients carried the MYBPC3-Gly999-Gln1004del mutation, while in the two other patients, the
mutations were unknown. Two control hiPSC lines were generated from dermal fibroblasts
using retroviruses, while all patient hiPSC lines and one control hiPSC line were derived from
T lymphocytes or peripheral blood with Sendai viruses. They used a mixture of EBs derived
from all three patients in their experiments [17]. In our publication, we derived hiPSC lines
from two patients carrying the MYBPC3-Gln1061X mutation and from two patients carrying
the TPM1-Asp175Asn mutation. The ages and clinical symptoms of our patients varied from
asymptomatic to a patient suffering from atrial fibrillation accompanied with substantial
thickening of interventricular septum. Two unrelated hiPSC lines derived from healthy
volunteers were used as control cells. hiPSCs were derived from fibroblasts using either retro-
or Sendai viruses. All hiPSC-derived HCM cardiomyocytes were significantly larger than
hiPSC-derived control cardiomyocytes [15].
In addition to cell size, myofibrillar disarray has been studied in three of the publications.
However, in all publications, different methods and criteria have been used to quantify the
disarray, and the results can be subjective. Han et al. showed that HCM hiPSC-derived
cardiomyocytes have more disrupted sarcomeres than cardiomyocytes derived from control
hiPSCs. However, the authors did not present any criteria to determine how the disruption
was qualified [14]. In Tanaka et al. [17], cardiomyocytes were qualified with myofibrillar
disarray if over 50% of the myofibrils intersected with each other. In Lan et al. [16], cardio‐
myocytes that had more than 25% of their cell area exhibiting punctate TnT distribution were
considered disorganized. The overall morphology of hiPSC-derived cardiomyocytes is not
mature, and their structure is often unorganized; this is also the case in cardiomyocytes derived
from control hiPSCs. We did not report myofibrillar disarray due to the lack of proper
quantitation criteria for this phenomenon.
Electrophysiological properties of hiPSC-derived cardiomyocytes have been studied in three
of the publications. In our study, the APD90 was significantly increased in hiPSC-derived
cardiomyocytes carrying the TPM1-Asp175Asn mutation or the MYBPC3-Gln1061X mutation.
Additionally, the action potential duration 90 (APD90) was significantly longer in cardiomyo‐
cytes carrying the TPM1-Asp175Asn mutation compared to cardiomyocytes carrying the
MYBPC3-Gln1061X mutation. Although the numbers of cardiomyocytes exhibiting arrhyth‐
mias (delayed after depolarizations (DADs) and early after depolarizations (EADs) were
similar for both mutations, the DAD rate was higher in cardiomyocytes carrying the MYBPC3-
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Gln1061X mutation than in control cardiomyocytes [15]. Lan et al. observed more cardiomyo‐
cytes exhibiting DADs in hiPSC-derived HCM cell populations carrying the MYH7-
Arg663His mutation than in control cardiomyocyte populations. In addition, the DAD rate was
significantly higher in these cells. Significant differences were observed only 30 days after the
initiation of cardiac differentiation [16]. Han and co-workers [14] demonstrated a marked
prolongation of APD in HCM hiPSC-derived cardiomyocytes carrying the MYH7-Arg442Gly
mutation but no increased DAD ratio.
Changes in Ca2+ handling properties are considered to be one of the earliest pathophysiological
mechanisms in HCM. In our study, the proportion of cardiomyocytes with abnormal Ca2+
transients was approximately 20% for hiPSC-derived control cardiomyocytes, 42% for
cardiomyocytes carrying the TPM1-Asp175Asn mutation and 21% for cardiomyocytes carrying
the MYBPC3-Gln1061X mutation at basic conditions. Lan and co-workers [16] reported that
approximately 20% of hiPSC-derived HCM cardiomyocytes carrying the MYH7-Arg663His
mutation had irregularities in their Ca2+ handling properties on day 30 and approximately 30%
on day 40 after initiating cardiac differentiation, while in control cardiomyocytes, the propor‐
tion was approximately 5% at all timepoints. Han et al. [14] reported that approximately 20%
of hiPSC-derived cardiomyocytes (MYH7-Arg442Gly) had abnormal Ca2+ handling properties,
while no control hiPSC-derived cardiomyocytes had abnormalities. Similar to the characteri‐
zation of disrupted sarcomeres, these data are also subjective, and the qualification or quan‐
tification criteria are rarely stated in publications. Thus, the results obtained in different
publications are not directly comparable. For example, the portion of control hiPSC-derived
cardiomyocytes, which have abnormalities in their Ca2+ handling properties varies from 0% to
20% in different publications. However, it is apparent that cardiomyocytes with HCM
mutation have more abnormalities in their Ca2+ transients than control cardiomyocytes.
The publication from Birket et al. is to date the only one focused on studying the contraction
forces of HCM hiPSC-derived cardiomyocytes. They studied cardiomyocytes derived from
three individual patient hiPSC lines carrying MYBPC3-c.2373dupG mutation and two unrelat‐
ed control hiPSC lines [13]. These hiPSC lines, derived from fibroblasts by lentiviruses, have
been published earlier by Dambrot et al [88]. To be able to detect the beating forces from hiPSC-
derived cardiomyocytes, Birket et al. [13] used triiodothyronine hormone (T3), insulin-like
growth factor 1 (IGF-1), and dexamethasone to enhance their bioenergetics and contractile
force generation. In these optimized conditions, decreased force generation was observed in
hiPSC-derived cardiomyocytes carrying the MYBPC3-c.2373dupG mutation. The impact of
mutation was confirmed by studying the generation of force in cardiomyocytes derived from
MYBPC3 knockdown hESCs [13].
4.2. Variable phenotype of hypertrophic cardiomyopathy
The primary cause of HCM is a mutation in a sarcomeric gene, while changes in Ca2+ handling
properties, energy deficiency, ion channel remodeling, and microvascular dysfunction are
thought to be the earliest pathophysiological mechanisms that play a role in disease progres‐
sion [89]. However, the reasons why progressive changes initiated by these primary mutations
occur in one individual and not in others are still largely unknown. Many mechanisms related
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to the variable phenotype of HCM have been proposed, including additional mutations,
genetic modifiers, epigenetic factors, environment and function of protein quality systems.
These additional disease modifiers are thought to impact on the development of mild HCM
phenotype to end-stage, in which the functionality of the heart is disrupted [90]. Convention‐
ally, HCM has been studied with animal models or patient samples obtained from surgical
myectomy. However, animal models carry only the mutated gene, and although they contain
the entire genome of an HCM patient, myectomy samples are obtained from patients in the
late stage of HCM development. While HCM leads to progressive heart failure, the major
difficulty in studying the pathophysiological mechanisms leading to HCM has been the lack
of tissue at the early stages of disease development. Thus, hiPSC models represent a valuable
tool to study HCM in vitro.
In our study, we could not detect the mutated MYBPC protein in hiPSC-derived cardiomyo‐
cytes carrying the MYBPC3-Gln1061X mutation, which is in line with previous studies using
human myectomy samples and hiPSC-derived cardiomyocytes [17, 87, 91, 92]. The total
amount of the MYBPC protein was slightly reduced in our study in cardiomyocytes carrying
the MYBPC3-Gln1061X mutation compared to hiPSC-derived control cardiomyocytes [15].
Similarly, Birket et al. [13] observed a decrease in MYBPC protein relative to α-actinin in their
hiPSC-derived cardiomyocytes carrying MYBPC3-c.2373dupG mutation, which they suggest‐
ed to be the reason for the decreased traction force. The dosage of the mutated gene is one of
the factors that has been proposed to affect the severity of the observed clinical phenotype.
HCM is inherited in an autosomal dominant pattern, and thus, both mutated and wildtype
proteins are expected to be incorporated into the sarcomere [90]. However, the expression of
the mutated protein can be regulated on many levels. In particular, the MYBPC3 mutations
leading to truncated proteins can be directed toward degradation by nonsense-mediated
mRNA decay, ubiquitin proteasome system (UPS), and the autophagy/lysosomal pathway,
which leads to haploinsufficiency [93]. The age-related decline of these protein quality systems
has been suggested to effect the progression of HCM [90]. The amount of the wildtype MYBPC
protein varies in patient tissue samples, which might correlate with the clinical phenotypes
observed in patients [92, 92]. Another mechanism affecting the dosage of the mutated gene
and thus disease severity could be allelic imbalance, which indicates differences in the
expression levels of mutated and wildtype alleles [93, 94].
Protein phosphorylation is one of the most important post-translational modifications, which
has also been suggested to affect disease development. For example, the reduced phosphory‐
lation of TnI and MYBPC has been related to increased myofilament Ca2+ sensitivity, which is
a common feature of HCM [95]. However, Ca2+ sensitivity has also been suggested to be a
primary consequence of HCM. Additionally, Ca2+ sensitivity has been proposed to increase
arrhythmia sensitivity either by increasing the Ca2+ binding affinity in the cytosol, which could
lead to remodeling of action potentials and thus trigger arrhythmias, or by affecting energy
consumption and increasing arrhythmia susceptibility via stress [90, 96, 97].
Some HCM patients have been shown to carry more than just one mutation in their genotype,
and patients carrying multiple mutations have been associated with more severe symptoms
or earlier onset of disease [76, 78]. Other genetic mechanisms include genetic modifiers, which
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can be either near or distantly located DNA variants that influence the expression of the
mutated gene [76]. Additionally, epigenetic changes, which cannot be explained by the DNA
sequence itself, have been suggested to contribute to the progression of HCM. These mecha‐
nisms include the methylation of GpC islands by DNA methyltransferases, histone modifica‐
tion, miRNAs and long non-coding RNAs (lncRNAs), which can lead to the altered regulation
of genes [76].
4.3. Challenges in modeling hypertrophic cardiomyopathy with human induced
pluripotent stem cells
The major limitation when using hiPSC-derived cardiomyocytes in disease modeling is the
immature nature of these cells. The characteristics of hPSC-derived cardiomyocytes and the
differences between these and adult human cardiomyocytes have recently been reviewed [98].
Compared to adult cardiomyocytes, the sarcomeric structures of hPSC-derived cardiomyo‐
cytes are unorganized, they lack clear T tubules, they have different ion channel profiles, and
their Ca2+ handling is immature. In addition, the shapes of hPSC-derived cardiomyocytes vary
from circular to star-shaped, while adult human cardiomyocytes are rod-shaped in vivo.
Overall, the phenotype of hPSC-derived cardiomyocytes is thought to more closely resemble
that of fetal cardiomyocytes than adult cardiomyocytes [98]. At the moment, much effort is
being expended to obtain more mature cardiomyocytes. In addition to culture conditions and
the long-term culture of cardiomyocytes, other techniques such as electrical and mechanical
stimulation, as well as engineered heart tissue (EHT) structures, have been developed [99–102].
Another issue related to the study of HCM with hiPSC-derived cardiomyocytes is related to
the assumption that cell types other than cardiomyocytes might be directly involved in the
progression of HCM. For example, microvascular dysfunction is thought to be the primary
reason for replacement-type fibrosis observed in HCM patients [90]. Thus, it is important to
consider whether studying HCM at the single cell level is sufficient to obtain an exact picture
of the disease mechanisms. EHT structures and cardiovascular constructs, consisting of
various cell types could be useful in this context [102, 103].
As discussed above, in addition to primary HCM gene mutations, gene modifiers and
epigenetic changes might also have an effect on disease development and progression. In all
published reports, the phenotypes of HCM hiPSC-derived cardiomyocytes have been com‐
pared to control hiPSC-derived cardiomyocytes established from related or non-related
healthy individuals [13–17]. Currently, useful gene-editing approaches, including clustered
regularly interspaced short palindromic repeats (CRISPR) and transcription activator-like
effector nuclease (TALEN) techniques, are available, and they can be used either to create
mutations or correct existing mutations in an hiPSC line, thus generating genotype-matched
isogenic control lines [104]. When considering the variable phenotypes of HCM patients, these
isogenic control hiPSCs would be useful when further studying HCM disease mechanisms.
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5. Conclusions
Although, the current methods for studying cardiomyopathies in vitro with patient-specific
cardiomyocytes are far from optimal, we and others have been able to create hiPSC models
with HCM phenotype. hiPSC-derived cardiomyocytes can also be utilized to study the effects
of genetic modifiers and epigenetic factors on disease progression between different individ‐
uals, which has been difficult when using animal models or samples from surgical myectomy.
However, particularly in the case of HCM associated with highly variable phenotypes, it would
be important to optimize cardiac differentiation and cell culture conditions. The study design
becomes highly valuable, and the culture conditions should be similar for both control and
disease-specific cardiomyocytes. When experiments are thoroughly designed, the results
obtained from these studies would be more robust and reliable. Nonetheless, hiPSC-derived
HCM in vitro models represent a valuable tool to study the pathophysiological mechanisms
of HCM as well as to test novel drug therapies developed to prevent disease progression and
potentially optimize treatments in a mutation-specific manner.
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